CT2211/2026 - Framework Contract for the supply of Selective Janus Kinase 1 Inhibitor Tablets/Prolonged Release Tablets/Capsules for IBD
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
45 / 100
Risk factors
Award criteria and selection criteria are not disclosed, making bid preparation speculative.
Framework contract may not guarantee any minimum purchase volume.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- EUR 5.6M estimated value
- Supplies contract
- 1 lot
- Supply of Selective Janus Kinase 1 Inhibitor Tablets/Prolonged Release Tablets/Capsules for Inflammatory Bowel Disease (IBD)
- Framework contract; no quantities or minimum spend specified
Show full summary
This is an open procedure framework contract for the supply of selective Janus Kinase 1 inhibitor tablets/prolonged release tablets/capsules for inflammatory bowel disease (IBD). The contract is for a single lot with an estimated total value of €5,608,254.60. The buyer is the Department of Contracts in Malta. The deadline for submission is 15 July 2026 at 07:30 (Malta time). Electronic submission is required in English. The notice does not disclose award or selection criteria; only an ESPD (European Single Procurement Document) is referenced. No procurement documents were analyzed beyond the notice.
Risks
Award criteria and selection criteria are not disclosed, making bid preparation speculative.
Framework contract may not guarantee any minimum purchase volume.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must supply pharmaceutical products classified under CPV 33693100
Administrative
- Electronic submission via eTenders Malta portal
- Tender must be submitted in English
Requirements may be incomplete.
Buyer
Name
Department of Contracts
Location
Floriana, MLT
Website
Buyer profile
Identifier
MT25645419
Lots (1)
LOT-0001
CT2211/2026 - Framework Contract for the supply of Selective Janus Kinase 1 Inhibitor Tablets/Prolonged Release Tablets/Capsules for IBD
Supply of selective JAK1 inhibitor tablets/prolonged release tablets/capsules for IBD.
EUR 5.6M
Estimated value
Location
Category
Deadline
Award details
Value note
Show original TED data
Original TED description
CT2211/2026 - Framework Contract for the supply of Selective Janus Kinase 1 Inhibitor Tablets/Prolonged Release Tablets/Capsules for IBD
Procurement Details
- Publication date
- 10 Jun 2026
- Notice type
- Contract notice — standard
- Languages
- English
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 400302-2026
- Source notice ID
- f6d13a04-f596-49cd-9767-d90b4901e4bd
Documents (2)
Similar tenders
Romania – Pharmaceutical products – Furnizare MEDICAMENTE, pe o perioada de 24 luni la Spitalul Orasenesc Gura Humorului
Poland – Medicinal products for the blood, blood-forming organs and the cardiovascular system – Dostawa produktów leczniczych dla krwi, organów krwiotwórczych oraz układu krążenia, toksyn, środków leczniczych dla układu oddechowego, środków przeciwnowotworowych i immunomodulacyjnych stosowanych w ramach programów lekowych i chemioterapii, immunoglobulin oraz środków antywirusowych do użytku ogólnoustrojowego dla SPWSZ w Szczecinie
Malta – Toxins – CT2183/2026 - Framework Contract for the supply of Sulphur Hexaflouride 8 microlitres/ml Powder and Solvent for Dispersion for Injection
Malta – Toxins – CT2124/2026 - FRAMEWORK CONTRACT FOR THE SUPPLY OF INHALED LONG-ACTING BETA 2 AGONIST FOR CHILDREN BETWEEN 4 AND 12 YEARS OF AGE (SALMETEROL OR FORMOTEROL)
Hungary – Toxins – K2638 Patkányírtáshoz szükséges irtószerek beszerz
Poland – Medicinal products for the blood, blood-forming organs and the cardiovascular system – Dostawa produktów leczniczych dla krwi, organów krwiotwórczych oraz układu krążenia, toksyn, środków leczniczych dla układu oddechowego, środków przeciwnowotworowych i immunomodulacyjnych stosowanych w ramach programów lekowych i chemioterapii, immunoglobulin oraz środków antywirusowych do użytku ogólnoustrojowego dla SPWSZ w Szczecinie
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
45 / 100
Risk factors
Award criteria and selection criteria are not disclosed, making bid preparation speculative.
Framework contract may not guarantee any minimum purchase volume.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications